A live-attenuated pneumococcal vaccine elicits CD4+ T-cell dependent class switching and provides serotype independent protection against acute otitis media

Jason W. Rosch, Amy R. Iverson, Jessica Humann, Beth Mann, Geli Gao, Peter Vogel, Michael Mina, Kyle A. Murrah, Antonia C. Perez, W. Edward Swords, Elaine I. Tuomanen, Jonathan Mccullers

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Acute otitis media (AOM) caused by Streptococcus pneumoniae remains one of the most common infectious diseases worldwide despite widespread vaccination. A major limitation of the currently licensed pneumococcal vaccines is the lack of efficacy against mucosal disease manifestations such as AOM, acute bacterial sinusitis and pneumonia. We sought to generate a novel class of live vaccines that (1) retain all major antigenic virulence proteins yet are fully attenuated and (2) protect against otitis media. A live vaccine candidate based on deletion of the signal recognition pathway component ftsY induced potent, serotype-independent protection against otitis media, sinusitis, pneumonia and invasive pneumococcal disease. Protection was maintained in animals coinfected with influenza virus, but was lost if mice were depleted of CD4+ T cells at the time of vaccination. The live vaccine induced a strong serum IgG2a and IgG2b response that correlated with CD4+ T-cell mediated class switching. Deletion of genes required for microbial adaptation to the host environment is a novel live attenuated vaccine strategy yielding the first experimental vaccine effective against pneumococcal otitis media.

Original languageEnglish (US)
Pages (from-to)141-154
Number of pages14
JournalEMBO Molecular Medicine
Volume6
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Immunoglobulin Class Switching
Pneumococcal Vaccines
Attenuated Vaccines
Otitis Media
T-Lymphocytes
Vaccines
Sinusitis
Vaccination
Microbial Genes
Pneumococcal Pneumonia
Bacterial Pneumonia
Gene Deletion
Streptococcus pneumoniae
Orthomyxoviridae
Communicable Diseases
Virulence
Signal Transduction
Serogroup
Serum
Proteins

All Science Journal Classification (ASJC) codes

  • Molecular Medicine

Cite this

A live-attenuated pneumococcal vaccine elicits CD4+ T-cell dependent class switching and provides serotype independent protection against acute otitis media. / Rosch, Jason W.; Iverson, Amy R.; Humann, Jessica; Mann, Beth; Gao, Geli; Vogel, Peter; Mina, Michael; Murrah, Kyle A.; Perez, Antonia C.; Edward Swords, W.; Tuomanen, Elaine I.; Mccullers, Jonathan.

In: EMBO Molecular Medicine, Vol. 6, No. 1, 01.01.2014, p. 141-154.

Research output: Contribution to journalArticle

Rosch, JW, Iverson, AR, Humann, J, Mann, B, Gao, G, Vogel, P, Mina, M, Murrah, KA, Perez, AC, Edward Swords, W, Tuomanen, EI & Mccullers, J 2014, 'A live-attenuated pneumococcal vaccine elicits CD4+ T-cell dependent class switching and provides serotype independent protection against acute otitis media', EMBO Molecular Medicine, vol. 6, no. 1, pp. 141-154. https://doi.org/10.1002/emmm.201202150
Rosch, Jason W. ; Iverson, Amy R. ; Humann, Jessica ; Mann, Beth ; Gao, Geli ; Vogel, Peter ; Mina, Michael ; Murrah, Kyle A. ; Perez, Antonia C. ; Edward Swords, W. ; Tuomanen, Elaine I. ; Mccullers, Jonathan. / A live-attenuated pneumococcal vaccine elicits CD4+ T-cell dependent class switching and provides serotype independent protection against acute otitis media. In: EMBO Molecular Medicine. 2014 ; Vol. 6, No. 1. pp. 141-154.
@article{ae368aa63a3c4604b99391c50c6218a1,
title = "A live-attenuated pneumococcal vaccine elicits CD4+ T-cell dependent class switching and provides serotype independent protection against acute otitis media",
abstract = "Acute otitis media (AOM) caused by Streptococcus pneumoniae remains one of the most common infectious diseases worldwide despite widespread vaccination. A major limitation of the currently licensed pneumococcal vaccines is the lack of efficacy against mucosal disease manifestations such as AOM, acute bacterial sinusitis and pneumonia. We sought to generate a novel class of live vaccines that (1) retain all major antigenic virulence proteins yet are fully attenuated and (2) protect against otitis media. A live vaccine candidate based on deletion of the signal recognition pathway component ftsY induced potent, serotype-independent protection against otitis media, sinusitis, pneumonia and invasive pneumococcal disease. Protection was maintained in animals coinfected with influenza virus, but was lost if mice were depleted of CD4+ T cells at the time of vaccination. The live vaccine induced a strong serum IgG2a and IgG2b response that correlated with CD4+ T-cell mediated class switching. Deletion of genes required for microbial adaptation to the host environment is a novel live attenuated vaccine strategy yielding the first experimental vaccine effective against pneumococcal otitis media.",
author = "Rosch, {Jason W.} and Iverson, {Amy R.} and Jessica Humann and Beth Mann and Geli Gao and Peter Vogel and Michael Mina and Murrah, {Kyle A.} and Perez, {Antonia C.} and {Edward Swords}, W. and Tuomanen, {Elaine I.} and Jonathan Mccullers",
year = "2014",
month = "1",
day = "1",
doi = "10.1002/emmm.201202150",
language = "English (US)",
volume = "6",
pages = "141--154",
journal = "EMBO Molecular Medicine",
issn = "1757-4676",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - A live-attenuated pneumococcal vaccine elicits CD4+ T-cell dependent class switching and provides serotype independent protection against acute otitis media

AU - Rosch, Jason W.

AU - Iverson, Amy R.

AU - Humann, Jessica

AU - Mann, Beth

AU - Gao, Geli

AU - Vogel, Peter

AU - Mina, Michael

AU - Murrah, Kyle A.

AU - Perez, Antonia C.

AU - Edward Swords, W.

AU - Tuomanen, Elaine I.

AU - Mccullers, Jonathan

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Acute otitis media (AOM) caused by Streptococcus pneumoniae remains one of the most common infectious diseases worldwide despite widespread vaccination. A major limitation of the currently licensed pneumococcal vaccines is the lack of efficacy against mucosal disease manifestations such as AOM, acute bacterial sinusitis and pneumonia. We sought to generate a novel class of live vaccines that (1) retain all major antigenic virulence proteins yet are fully attenuated and (2) protect against otitis media. A live vaccine candidate based on deletion of the signal recognition pathway component ftsY induced potent, serotype-independent protection against otitis media, sinusitis, pneumonia and invasive pneumococcal disease. Protection was maintained in animals coinfected with influenza virus, but was lost if mice were depleted of CD4+ T cells at the time of vaccination. The live vaccine induced a strong serum IgG2a and IgG2b response that correlated with CD4+ T-cell mediated class switching. Deletion of genes required for microbial adaptation to the host environment is a novel live attenuated vaccine strategy yielding the first experimental vaccine effective against pneumococcal otitis media.

AB - Acute otitis media (AOM) caused by Streptococcus pneumoniae remains one of the most common infectious diseases worldwide despite widespread vaccination. A major limitation of the currently licensed pneumococcal vaccines is the lack of efficacy against mucosal disease manifestations such as AOM, acute bacterial sinusitis and pneumonia. We sought to generate a novel class of live vaccines that (1) retain all major antigenic virulence proteins yet are fully attenuated and (2) protect against otitis media. A live vaccine candidate based on deletion of the signal recognition pathway component ftsY induced potent, serotype-independent protection against otitis media, sinusitis, pneumonia and invasive pneumococcal disease. Protection was maintained in animals coinfected with influenza virus, but was lost if mice were depleted of CD4+ T cells at the time of vaccination. The live vaccine induced a strong serum IgG2a and IgG2b response that correlated with CD4+ T-cell mediated class switching. Deletion of genes required for microbial adaptation to the host environment is a novel live attenuated vaccine strategy yielding the first experimental vaccine effective against pneumococcal otitis media.

UR - http://www.scopus.com/inward/record.url?scp=84891950263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891950263&partnerID=8YFLogxK

U2 - 10.1002/emmm.201202150

DO - 10.1002/emmm.201202150

M3 - Article

VL - 6

SP - 141

EP - 154

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

SN - 1757-4676

IS - 1

ER -